ÜLDANDMED

    Nimi: Peeter Padrik

    Töötelefon: 731 9800

    E-mail: See e-posti aadress on spämmirobotite eest kaitstud. Selle nägemiseks peab su veebilehitsejas olema JavaSkript sisse lülitatud.

    Keeled: eesti, inglise, vene

HARIDUS JA TEENISTUSKÄIK

Teenistuskäik
2017- ... SA Tartu Ülikooli Kliinikum, hematoloogia-onkoloogia kliinik
2015- ... SA Tartu Ülikooli Kliinikum, vähikeskus, direktor
2016-... Tartu Ülikool, Meditsiiniteaduste valdkond, Kliinilise meditsiini instituut, hematoloogia-onkoloogia kliinik, onkoloogia dotsent (0.25)
2000 - 2016 SA Tartu Ülikooli Kliinikum, hematoloogia-onkoloogia kliinik, direktor
1997 - 1999 SA Tartu Ülikooli Kliinikum, Onkoloogiahaigla, peaarst
1996 - 1997 Tartu Ülikooli Kliinikum, Onkoloogiahaigla, peaarsti asetäitja
1993 - 1996 Tartu Ülikooli Kliinikum, Onkoloogiahaigla, onkoloog
1992 - 1993 Eesti Onkoloogiakeskus, onkoloog
1991 - 1992 Eksperimentaalse ja Kliinilise Meditsiini Instituut, nooremteadur

Haridus
1990-1991 Tartu Kliiniline Haigla, internatuur kirurgia erialal
1984-1990 Tartu Ülikool, arstiteaduskond
Teadusorganisatsiooniline- ja administratiivne tegevus
Eesti Onkoteraapia Ühingu juhatuse liige
Sotsiaalministeeriumi onkoloogia erialakomisjoni liige
European Society for Medical Oncology liige
American Society of Clinical Oncology liige

RAVIALANE SPETSIALISEERUMINE
Soliidtuumorite medikamentoosne onkoloogia

ENESETÄIENDUS (viimased 5a)
Clevelend Clinic Preceptorship Program in Renal Cell Cancer Management, 2016
American Society of Clinical Oncology Annual Meeting, 2016
European Breast Cancer Conference, 2016
Conference of Molecular Analysis for Personalised Therapy, 2015
European Cancer Congress, 2015
European Society for Medical Oncology Congress, 2014
American Society of Clinical Oncology Annual Meeting, 2014
SDA Bocconi School of Management (Milano) Program for Oncology Leaders in Europe, 2013-2014
American National Comprehensive Cancer Network Annual Conference, 2013
Oncology Leaders Summit, Deutsche Gesellschaft für Senologie, 2012
European Society for Medical Oncology Congress, 2012
European Forum on Oncology, 2012
Advances in Cancer Therapy, 2012

TEADUSTEGEVUS
Teaduskraadi info: Doktorikraad, 2007: “Renal Cell Carcinoma: Changes in Natural History and Treatment of Metastatic Disease”, Tartu Ülikool


Teadustöö põhisuunad
Neeruvähi, rinnavähi, melanoomi ravi

PUBLIKATSIOONID (1.1-1.3)

1.1. - 19 publikatsiooni
Padrik, P.; Valter, A.; Valter, E.; Baburin, A.; Innos, K. (2017). Trends in incidence and survival of cutaneous malignant melanoma in Estonia: a population-based study. Acta Oncologica, 56 (1), 52−58
Innos, K; Valvere, V; Padrik, P; Eelma, E; Kütner, R; Lehtsaar, J; Tekkel, M (2016). Mammography use and mode of detection among breast cancer patients in Estonia. Women & Health, 56 (2), 129−140, 03630242.2015.1086468.
Harrison, Simon J; Mainwaring, Paul; Price, Timothy; Millward, Michael J; Padrik, Peeter; Underhill, Craig R; Cannell, Paul K; Reich, Steven D; Trikha, Mohit; Spencer, Andrew (2016). Phase I Clinical Trial of Marizomib (NPI-0052) in Patients with Advanced Malignancies Including Multiple Myeloma: Study NPI-0052-102 Final Results. Clinical cancer research : an official journal of the American Association for Cancer Research, 18 (Sep 15;22), 4599−4566.
Innos, K.; Padrik, P.; Valvere, V.; Aareleid, T. (2015). Sex differences in cancer survival in Estonia: a population-based study. BMC Cancer, 15 (72), 72, s12885-015-1080-9.
Baburin, Aleksei; Aareleid, Tiiu; Padrik, Peeter; Valvere, Vahur; Innos, Kaire (2014). Time trends in population-based breast cancer survival in Estonia: Analysis by age and stage. Acta Oncologica, 53(2), 226 - 234.
Innos, K; Padrik, P; Valvere, V; Eelma, E; Kütner, R; Lehtsaar, J; Tekkel, M (2013). Identifying women at risk for delayed presentation of breast cancer: a cross-sectional study in Estonia . BMC Public Health, 13, 947
Vrdoljak, E.; Ciuleanu, T.; Kharkevich, G.; Mardiak, J.; Mego, M.; Padrik, P.; Petruželka, L.; Purkalne, G.; Shparyk, Y.; Skrbinc, B.; Szczylik, C.; Torday, L. (2012). Optimizing treatment for patients with metastatic renal cell carcinoma in the central and Eastern European region. Expert Opinion on Pharmacotherapy, 13(2), 159 - 174.
Kasari, Marje; Padrik, Peeter; Vaasa, Angela; Saar, Kristi; Leppik, Krista; Soplepmann, Jaan; Uri, Asko (2012). Time-gated luminescence assay using nonmetal probes for determination of protein kinase activity-based disease markers. Analytical Biochemistry, 422(2), 79 - 88.
Mieog, J.; Morden, J.; Bliss, J.; Coombes, R.; van de Velde, C.; Intergroup Investigators, inc. Padrik, P. (2012). Carpal tunnel syndrome and musculoskeletal symptoms in postmenopausal women with early breast cancer treated with exemestane or tamoxifen after 2-3 years of tamoxifen: a retrospective analysis of the Intergroup Exemestane Study. The Lancet Oncology, 13(4), 420 - 432.
Smith, I.; Pierga, J.; Biganzoli, L.; Cortés-Funes, H.; Thomssen, C.; Pivot, X.; Fabi, A.; Xu, B.; Stroyakovskiy, D.; Franke, F.; Kaufman, B.; Mainwaring, P.; Pienkowski, T.; De Valk, B.; Kwong, A.; González-Trujillo, JL.; Koza, I.; Petrakova, K.; Pereira, D.; Pritchard, K; ATHENA Study Group incl. Padrik, P. (2011). First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2,251 patients. Annals of Oncology, 22(3), 595 - 602.
Slamon, D.; Eiermann, W.; Robert, N.; Pienkowski, T.; Martin, M.; Press, M.; Mackey, J.; Glaspy, J.; Chan, A.; Pawlicki, M.; Pinter, T.; Valero, V.; Liu, M.; Sauter, G.; von Minckwitz, G.; Visco, F.; Bee, V.; Buyse, M.; Bendahmane, B.; Tabah-Fisch, I.; Lindsay, M.; Riva, A.; Crown, J.; Breast Cancer International Research Group incl. Padrik, P. (2011). Adjuvant trastuzumab in HER2-positive breast cancer. New England Journal of Medicine, Oct. 6, 1336 - 1338.
Steger, G.; Abrahámová, J.; Bacanu, F.; Brincat, S.; Brize, A.; Cesas, A.; Cufer, T.; Dank, M.; Duchnowska, R.; Eniu, A.; Jassem, J.; Kahán, Z.; Matos, E.; Padrik, P.; Plāte, S.; Pokker, H.; Purkalne, G.; Timcheva, C.; Tzekova, V.; Vyzula, R.; Zielinski, C. (2010). Current standards in the treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central European Consensus Panel. Wiener Klinische Wochenschrift, 122(11-12), 368 - 379.
Tamboom, K.; Kaasik, K.; Arsavskaja, J.; Tekkel, M., Lilleorg, A.; Padrik, P.; Metspalu, A.; Veidebaum, T. (2010). BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia. Hereditary Cancer in Clinical Practice, 8(4), 1 - 4.
Padrik, P.; Saar, H. (2009). Thymidine phosphorylase as a prognostic factor in renal cell carcinoma. International Urology and Nephrology, 295-298.
Kenemans, P.; Bundred, N.; Foidart, J.; Kubista, E.; von Schoultz, B.; Sismondi, P.; Vassilopoulou-Sellin, R.; Yip, C.; Egberts, J.; Mol-Arts, M.; Mulder, R.; vanOs, S.; Beckmann, M.; Liberate Study, G. (2009). Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. The Lancet Oncology, 10, 135 - 146.
Padrik, P.; Kirsimägi, Ü.; Everaus, H. (2007). Changes in the natural history of renal cancer: comparison of Estonian data from the periods 1986-1988 and 1996-1998. International Urology and Nephrology, 39(1), 35 - 41.
Padrik, P.; Leppik, K.; Arak, A. (2004). Combination therapy with capecitabine and interferon alfa-2A in patients with advanced renal cell carcinoma: a phase II study. Urologic Oncology-Seminars and Original Investigations, 22(5), 387 - 392.
Bouzid, K.; Khalfallah, S.; Tujakowski, J.; Piko, B.; Purkalne, G.; Plate, S.; Padrik, P.; Serafy, M.; Pshevloutsky, E.; Boussard, B. (2003). A randomized phase II trial of irinotecan in combination with infusional or two different bolus 5-fluorouracil and folinic acid regimens as first-line therapy for advanced colorectal cancer. Annals of Oncology, 14(7), 1106 - 1114.
Padrik, P. (2003). Prognostic factors of immunotherapy in metastatic renal cell carcinoma. Medical Oncology, 20(4), 325 - 334.

1.3. - 7 publikatsiooni
Padrik, P.; Soplepmann, J.; Hussar, K.; Teras, J.; Teras, M.; Putnik, K.; Ojamaa, K.; Adamson, A.; Saretok, M. (2014). Kliinilise auditi „Naha melanoomi diagnostika ja ravi 2012. aastal esmashaigestunud patsientidel” kokkuvõte. Eesti Arst, 93 (8), 445−447.
Kallak, K.; Padrik, P. (2013). Tõenduspõhine rinnavähi kiiritusravi. Eesti Arst, 92(10), 575 - 580.
Padrik, P. (2011). Metastaatilise neeruvähi uued ravivõimalused . Eesti Arst, 90(1), 35 - 40.
Padrik, P., Eelma, E., Lehtsaar, J. (2007). Rinnavähi ravi arengusuunad . Eesti Arst, 86(11), 819 - 822.
Padrik, P.; Saar, H.; Leppik, K. (2006). Application of analysis of thymidine phosphorylase exprsssion in metastatic renal carcinoma tissue. Eesti Arst, 85(5), 297 - 300.
Padrik, P.; Saar, H.; Leppik, K. (2006). Tümidiini fosforülaasi ekspressiooni analüüsi rakendamine metastaatilise neeruvähiga patsientide kasvajakoes . Eesti Arst, 85(5), 297 - 300.
Padrik, P. (2002). Metastaatilise neeruvähi süsteemne ravi . Eesti Arst, 81(10), 631 - 637.

Uuendatud: 02.2017